Abstract
Summary
CRISPR (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that had previously infected the prokaryote. They are used to detect and destroy DNA from similar bacteriophages during subsequent infections. Hence these sequences play a key role in the antiviral (i.e. anti-phage) defense system of prokaryotes.
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms. This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.
Diagram of the CRISPR prokaryotic antiviral defense mechanism. The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages and provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA.
Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.
LPI (LP Information)' newest research report, the “CRISPR & Cas Genes Industry Forecast” looks at past sales and reviews total world CRISPR & Cas Genes sales in 2022, providing a comprehensive analysis by region and market sector of projected CRISPR & Cas Genes sales for 2023 through 2029. With CRISPR & Cas Genes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CRISPR & Cas Genes industry.
This Insight Report provides a comprehensive analysis of the global CRISPR & Cas Genes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CRISPR & Cas Genes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CRISPR & Cas Genes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CRISPR & Cas Genes and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CRISPR & Cas Genes.
The global CRISPR & Cas Genes market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CRISPR & Cas Genes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CRISPR & Cas Genes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CRISPR & Cas Genes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CRISPR & Cas Genes players cover CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd. and Horizon Discovery Group Plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CRISPR & Cas Genes market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Vector-based Cas
DNA-free Cas
Cell Line Engineering
Segmentation by application
Biotechnology and Pharmaceutical Companies
Academics and Government Research Institutes
Contract Research Organizations (CROs)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CRISPR Therapeutics
AstraZeneca
Addgene
Caribou Biosciences, Inc.
Cellectis
Editas Medicine, Inc.
Egenesis
F. Hoffmann-La Roche Ltd.
Horizon Discovery Group Plc
Genscrip
Danaher Corporation
Intellia Therapeutics, Inc.
Lonza
Merck KGaA
New England BioLabs
Takara Bio, Inc.
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms. This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.
Diagram of the CRISPR prokaryotic antiviral defense mechanism. The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages and provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA.
Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.
LPI (LP Information)' newest research report, the “CRISPR & Cas Genes Industry Forecast” looks at past sales and reviews total world CRISPR & Cas Genes sales in 2022, providing a comprehensive analysis by region and market sector of projected CRISPR & Cas Genes sales for 2023 through 2029. With CRISPR & Cas Genes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CRISPR & Cas Genes industry.
This Insight Report provides a comprehensive analysis of the global CRISPR & Cas Genes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CRISPR & Cas Genes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CRISPR & Cas Genes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CRISPR & Cas Genes and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CRISPR & Cas Genes.
The global CRISPR & Cas Genes market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CRISPR & Cas Genes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CRISPR & Cas Genes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CRISPR & Cas Genes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CRISPR & Cas Genes players cover CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd. and Horizon Discovery Group Plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CRISPR & Cas Genes market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Vector-based Cas
DNA-free Cas
Cell Line Engineering
Segmentation by application
Biotechnology and Pharmaceutical Companies
Academics and Government Research Institutes
Contract Research Organizations (CROs)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CRISPR Therapeutics
AstraZeneca
Addgene
Caribou Biosciences, Inc.
Cellectis
Editas Medicine, Inc.
Egenesis
F. Hoffmann-La Roche Ltd.
Horizon Discovery Group Plc
Genscrip
Danaher Corporation
Intellia Therapeutics, Inc.
Lonza
Merck KGaA
New England BioLabs
Takara Bio, Inc.
Synthego
Mammoth Biosciences
Inscripta, Inc.
Cibus
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CRISPR & Cas Genes Market Size 2018-2029
2.1.2 CRISPR & Cas Genes Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 CRISPR & Cas Genes Segment by Type
2.2.1 Vector-based Cas
2.2.2 DNA-free Cas
2.2.3 Cell Line Engineering
2.3 CRISPR & Cas Genes Market Size by Type
2.3.1 CRISPR & Cas Genes Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global CRISPR & Cas Genes Market Size Market Share by Type (2018-2023)
2.4 CRISPR & Cas Genes Segment by Application
2.4.1 Biotechnology and Pharmaceutical Companies
2.4.2 Academics and Government Research Institutes
2.4.3 Contract Research Organizations (CROs)
2.5 CRISPR & Cas Genes Market Size by Application
2.5.1 CRISPR & Cas Genes Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global CRISPR & Cas Genes Market Size Market Share by Application (2018-2023)
3 CRISPR & Cas Genes Market Size by Player
3.1 CRISPR & Cas Genes Market Size Market Share by Players
3.1.1 Global CRISPR & Cas Genes Revenue by Players (2018-2023)
3.1.2 Global CRISPR & Cas Genes Revenue Market Share by Players (2018-2023)
3.2 Global CRISPR & Cas Genes Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CRISPR & Cas Genes by Regions
4.1 CRISPR & Cas Genes Market Size by Regions (2018-2023)
4.2 Americas CRISPR & Cas Genes Market Size Growth (2018-2023)
4.3 APAC CRISPR & Cas Genes Market Size Growth (2018-2023)
4.4 Europe CRISPR & Cas Genes Market Size Growth (2018-2023)
4.5 Middle East & Africa CRISPR & Cas Genes Market Size Growth (2018-2023)
5 Americas
5.1 Americas CRISPR & Cas Genes Market Size by Country (2018-2023)
5.2 Americas CRISPR & Cas Genes Market Size by Type (2018-2023)
5.3 Americas CRISPR & Cas Genes Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CRISPR & Cas Genes Market Size by Region (2018-2023)
6.2 APAC CRISPR & Cas Genes Market Size by Type (2018-2023)
6.3 APAC CRISPR & Cas Genes Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe CRISPR & Cas Genes by Country (2018-2023)
7.2 Europe CRISPR & Cas Genes Market Size by Type (2018-2023)
7.3 Europe CRISPR & Cas Genes Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CRISPR & Cas Genes by Region (2018-2023)
8.2 Middle East & Africa CRISPR & Cas Genes Market Size by Type (2018-2023)
8.3 Middle East & Africa CRISPR & Cas Genes Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global CRISPR & Cas Genes Market Forecast
10.1 Global CRISPR & Cas Genes Forecast by Regions (2024-2029)
10.1.1 Global CRISPR & Cas Genes Forecast by Regions (2024-2029)
10.1.2 Americas CRISPR & Cas Genes Forecast
10.1.3 APAC CRISPR & Cas Genes Forecast
10.1.4 Europe CRISPR & Cas Genes Forecast
10.1.5 Middle East & Africa CRISPR & Cas Genes Forecast
10.2 Americas CRISPR & Cas Genes Forecast by Country (2024-2029)
10.2.1 United States CRISPR & Cas Genes Market Forecast
10.2.2 Canada CRISPR & Cas Genes Market Forecast
10.2.3 Mexico CRISPR & Cas Genes Market Forecast
10.2.4 Brazil CRISPR & Cas Genes Market Forecast
10.3 APAC CRISPR & Cas Genes Forecast by Region (2024-2029)
10.3.1 China CRISPR & Cas Genes Market Forecast
10.3.2 Japan CRISPR & Cas Genes Market Forecast
10.3.3 Korea CRISPR & Cas Genes Market Forecast
10.3.4 Southeast Asia CRISPR & Cas Genes Market Forecast
10.3.5 India CRISPR & Cas Genes Market Forecast
10.3.6 Australia CRISPR & Cas Genes Market Forecast
10.4 Europe CRISPR & Cas Genes Forecast by Country (2024-2029)
10.4.1 Germany CRISPR & Cas Genes Market Forecast
10.4.2 France CRISPR & Cas Genes Market Forecast
10.4.3 UK CRISPR & Cas Genes Market Forecast
10.4.4 Italy CRISPR & Cas Genes Market Forecast
10.4.5 Russia CRISPR & Cas Genes Market Forecast
10.5 Middle East & Africa CRISPR & Cas Genes Forecast by Region (2024-2029)
10.5.1 Egypt CRISPR & Cas Genes Market Forecast
10.5.2 South Africa CRISPR & Cas Genes Market Forecast
10.5.3 Israel CRISPR & Cas Genes Market Forecast
10.5.4 Turkey CRISPR & Cas Genes Market Forecast
10.5.5 GCC Countries CRISPR & Cas Genes Market Forecast
10.6 Global CRISPR & Cas Genes Forecast by Type (2024-2029)
10.7 Global CRISPR & Cas Genes Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 CRISPR Therapeutics
11.1.1 CRISPR Therapeutics Company Information
11.1.2 CRISPR Therapeutics CRISPR & Cas Genes Product Offered
11.1.3 CRISPR Therapeutics CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 CRISPR Therapeutics Main Business Overview
11.1.5 CRISPR Therapeutics Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca CRISPR & Cas Genes Product Offered
11.2.3 AstraZeneca CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Addgene
11.3.1 Addgene Company Information
11.3.2 Addgene CRISPR & Cas Genes Product Offered
11.3.3 Addgene CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Addgene Main Business Overview
11.3.5 Addgene Latest Developments
11.4 Caribou Biosciences, Inc.
11.4.1 Caribou Biosciences, Inc. Company Information
11.4.2 Caribou Biosciences, Inc. CRISPR & Cas Genes Product Offered
11.4.3 Caribou Biosciences, Inc. CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Caribou Biosciences, Inc. Main Business Overview
11.4.5 Caribou Biosciences, Inc. Latest Developments
11.5 Cellectis
11.5.1 Cellectis Company Information
11.5.2 Cellectis CRISPR & Cas Genes Product Offered
11.5.3 Cellectis CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Cellectis Main Business Overview
11.5.5 Cellectis Latest Developments
11.6 Editas Medicine, Inc.
11.6.1 Editas Medicine, Inc. Company Information
11.6.2 Editas Medicine, Inc. CRISPR & Cas Genes Product Offered
11.6.3 Editas Medicine, Inc. CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Editas Medicine, Inc. Main Business Overview
11.6.5 Editas Medicine, Inc. Latest Developments
11.7 Egenesis
11.7.1 Egenesis Company Information
11.7.2 Egenesis CRISPR & Cas Genes Product Offered
11.7.3 Egenesis CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Egenesis Main Business Overview
11.7.5 Egenesis Latest Developments
11.8 F. Hoffmann-La Roche Ltd.
11.8.1 F. Hoffmann-La Roche Ltd. Company Information
11.8.2 F. Hoffmann-La Roche Ltd. CRISPR & Cas Genes Product Offered
11.8.3 F. Hoffmann-La Roche Ltd. CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.8.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.9 Horizon Discovery Group Plc
11.9.1 Horizon Discovery Group Plc Company Information
11.9.2 Horizon Discovery Group Plc CRISPR & Cas Genes Product Offered
11.9.3 Horizon Discovery Group Plc CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Horizon Discovery Group Plc Main Business Overview
11.9.5 Horizon Discovery Group Plc Latest Developments
11.10 Genscrip
11.10.1 Genscrip Company Information
11.10.2 Genscrip CRISPR & Cas Genes Product Offered
11.10.3 Genscrip CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Genscrip Main Business Overview
11.10.5 Genscrip Latest Developments
11.11 Danaher Corporation
11.11.1 Danaher Corporation Company Information
11.11.2 Danaher Corporation CRISPR & Cas Genes Product Offered
11.11.3 Danaher Corporation CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Danaher Corporation Main Business Overview
11.11.5 Danaher Corporation Latest Developments
11.12 Intellia Therapeutics, Inc.
11.12.1 Intellia Therapeutics, Inc. Company Information
11.12.2 Intellia Therapeutics, Inc. CRISPR & Cas Genes Product Offered
11.12.3 Intellia Therapeutics, Inc. CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Intellia Therapeutics, Inc. Main Business Overview
11.12.5 Intellia Therapeutics, Inc. Latest Developments
11.13 Lonza
11.13.1 Lonza Company Information
11.13.2 Lonza CRISPR & Cas Genes Product Offered
11.13.3 Lonza CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Lonza Main Business Overview
11.13.5 Lonza Latest Developments
11.14 Merck KGaA
11.14.1 Merck KGaA Company Information
11.14.2 Merck KGaA CRISPR & Cas Genes Product Offered
11.14.3 Merck KGaA CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Merck KGaA Main Business Overview
11.14.5 Merck KGaA Latest Developments
11.15 New England BioLabs
11.15.1 New England BioLabs Company Information
11.15.2 New England BioLabs CRISPR & Cas Genes Product Offered
11.15.3 New England BioLabs CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 New England BioLabs Main Business Overview
11.15.5 New England BioLabs Latest Developments
11.16 Takara Bio, Inc.
11.16.1 Takara Bio, Inc. Company Information
11.16.2 Takara Bio, Inc. CRISPR & Cas Genes Product Offered
11.16.3 Takara Bio, Inc. CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Takara Bio, Inc. Main Business Overview
11.16.5 Takara Bio, Inc. Latest Developments
11.17 Synthego
11.17.1 Synthego Company Information
11.17.2 Synthego CRISPR & Cas Genes Product Offered
11.17.3 Synthego CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Synthego Main Business Overview
11.17.5 Synthego Latest Developments
11.18 Mammoth Biosciences
11.18.1 Mammoth Biosciences Company Information
11.18.2 Mammoth Biosciences CRISPR & Cas Genes Product Offered
11.18.3 Mammoth Biosciences CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Mammoth Biosciences Main Business Overview
11.18.5 Mammoth Biosciences Latest Developments
11.19 Inscripta, Inc.
11.19.1 Inscripta, Inc. Company Information
11.19.2 Inscripta, Inc. CRISPR & Cas Genes Product Offered
11.19.3 Inscripta, Inc. CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Inscripta, Inc. Main Business Overview
11.19.5 Inscripta, Inc. Latest Developments
11.20 Cibus
11.20.1 Cibus Company Information
11.20.2 Cibus CRISPR & Cas Genes Product Offered
11.20.3 Cibus CRISPR & Cas Genes Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Cibus Main Business Overview
11.20.5 Cibus Latest Developments
12 Research Findings and Conclusion